Scenesse

Active Ingredient(s): Afamelanotide
FDA Approved: * October 8, 2019
Pharm Company: * CLIVUNEL INC
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Scenesse Overview

Afamelanotide (melanotan I, brand name Scenesse) is a synthetic peptide and analogue of α-melanocyte stimulating hormone used to prevent skin damage from the sun in people with erythropoietic protoporphyria in Europe since January 2015, and the United States since October 2019. As a medicine sold under the brand name "Scenesse", it is administered in subcutaneous implant form; the implant lasts for two months. It is under development in other skin disorders in several jurisdictions. I...

Read more Scenesse Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Afamelanotide

Recent Scenesse Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Afamelanotide
  • Implant: 16mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Afamelanotide or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 26 January 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA